Effects of thyrotropin-releasing hormone in depression.

  title={Effects of thyrotropin-releasing hormone in depression.},
  author={Arthur J. Prange and Patricio P. Lara and Ian C. Wilson and Lacoe B. Alltop and George R. Breese},
  volume={2 7785},

Treatment of endogenous depression with oral thyrotropin‐releasing hormone and amitriptyline

The effect of thyrotropin‐releasing hormone (TRH) on the symptoms in six subjects with endogenous depression was studied in relation to the function of the hypothalamic‐pituitary‐thyroid axis and was

Treatment of endogenous depressions with Thyrotropin‐Releasing Hormone (TRH) under oral administration

  • J. Schmidt
  • Medicine, Psychology
    Acta psychiatrica Scandinavica
  • 1977
In a double‐blind study among six patients suffering from endogenous depression, three patients received Thyrotropin‐Releasing Hormone administered orally in doses of 20 mg three times a day for 3 weeks showed that TRH had no antidepressant effect.

Antidepressant Effect of Thyrotropin‐Releasing Hormone (TRH) and the Plasma Thyrotropin Levels in Depression

Patients with mental depression received thyrotropin‐releasing hormone (TSH) and imipramine, which was administered in place of TRH, revealed to have more effect on their depression.

The comparison of thyrotropin releasing hormone, luteinising hormone-releasing hormone and placebo in depressive patients using a double-blind cross-over technique

No significant differences could be seen between the treatments although transient elevations in mood were subjectively observed in endogenous-depressed patients.

Therapeutic Failure of Oral Thyrotropin‐Releasing Hormone in Depression

Contrary to some reports of TRH as an effective antidepressant, the results indicated not only failure of benefit but actual antitherapeutic effects in 3 of 6 treated patients as compared with placebo controls.

Continuation therapy in endogenous depression controlled by changes in the TRH stimulation test

Changes in the thyrotropin response to thyrotopin-releasing hormone were shown to be of predictive value and might be useful in the control of continuation therapy with antidepressants in patients with endogenous depression.



Enhancement of imipramine antidepressant activity by thyroid hormone.

Twenty euthyroid patients with retarded depression were studied to determine the possible role of alterations in thyroid function in the etiology and treatment of depression, and T3 was physiologically active, altering protein-bound iodine values and accelerating ankle reflex time.

Enhancement of imipramine by thyroid stimulating hormone: clinical and theoretical implications.

Thyroid stimulating hormone, when combined with imipramine, produces a more rapid recovery from depression than does imipramsine alone, but dose differences prevent accurate comparison.

Synthetic thyrotropin-releasing hormone. A potent stimulator of thyrotropin secretion in man.

TRH is a potent and nontoxic stimulator of TSH release in man and is a useful diagnostic compound in testing pituitary TSH reserve and the availability of TRH now makes possible the recognition of "hypothalamic" hypothyroidism.

Hormonal potentiation of imipramine and ECT in primary depression.

The results of this study, which are clearly negative, raise serious questions as to the efficacy of these hormones in enhancing the antidepressant activity of imipramine and ECT.

Thyrotropin-Releasing Hormone: Evidence for Thyroid Response to Intravenous Injection in Man

Observations of the response of the pituitary and thyroid glands to thyrotropin-releasing hormone to normal subjects may prove to be of value in simultaneously assessing the ability of these glands to respond to their trophic hormones.

Inhibition of thyrotropin response to thyrotropin-releasing hormone by small quantities of thyroid hormones.

The extreme sensitivity of TRH-induced TSH release to inhibition by the chronic treatment with small quantities of triiodothyronine and thyroxine which do not raise serum T(3) and T(4) levels above the normal ranges is demonstrated.

Preliminary observations on the effect of synthetic thyrotropin releasing factor on plasma thyrotropin levels in man.

Intravenous administration of synthetic TRF in doses of 250–750 μg stimulates a rise in plasma HTSH levels in normal individuals, and one of two euthyroid patients with a sella tumor appeared to respond suboptimally to TRF.

Thyrotropin response to thyrotropin releasing hormone in normal females over forty.

  • P. SnyderR. Utiger
  • Medicine, Biology
    The Journal of clinical endocrinology and metabolism
  • 1972
Females demonstrate no agerelated decline in TSH response to TRH, in contrast to males, which is virtually the same as the mean maximum ΔTSH response.

Thyroid hormone and tricyclic antidepressants in resistant depressions.

  • B. Earle
  • Medicine, Psychology
    The American journal of psychiatry
  • 1970
The author concludes that thyroid hormone potentiates the effects of the tricyclic antidepressants to some extent, but he suggests the need for further study in this area.